Ignite Creation Date:
2025-12-25 @ 12:56 AM
Ignite Modification Date:
2026-05-18 @ 8:18 PM
Study NCT ID:
NCT00337467
Status:
COMPLETED
Last Update Posted:
2010-07-19
First Post:
2006-06-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression
Sponsor:
Bristol-Myers Squibb
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
AI424-227
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Study Director
Old Organization:
Bristol-Myers Squibb